Enzo Biochem Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Revenue for the second quarter increased by 14% year-over-year.
- Life Science division's gross margin improved by 1,000 basis points to 49%.
- Net income for the second quarter was $1.1 million, a significant improvement from the prior year.
- Enzo ended the quarter with $60.2 million in cash and cash equivalents.
- The company's strategy focuses on sustainable revenue growth and operational efficiency.
- None.
Insights
The reported financial results by Enzo Biochem, Inc. indicate a robust year-over-year revenue growth of 14% in their Life Science division, a notable achievement considering the competitive nature of the biotech industry. The 25% increase in U.S. revenue underscores a strong domestic market presence, particularly in the burgeoning drug development and cell and gene therapy segments. This growth trajectory is commendable, as it reflects the company's strategic alignment with high-growth market areas.
The gross margin expansion from 39% to 49% is particularly impressive, highlighting improved operational efficiency and successful cost containment measures, such as workforce reductions. A 1,000 basis point improvement is significant and suggests a substantial enhancement in profitability. Investors should note the positive impact of such margin improvements on the company's bottom line, as evidenced by the reported net income of $1.1 million for the Life Science division, up from $0.2 million in the previous year.
The reduction in net loss from continuing operations and the overall net loss, along with an improved current ratio of 3.2, paints a picture of a company that is not only growing its top line but also strengthening its financial health. However, the decrease in cash and cash equivalents by $23.1 million due to the paydown of liabilities warrants attention, as it may affect the company’s liquidity in the short term. Despite this, the company's strategy of market focus and operational conservatism seems to be paying off, as evidenced by the consecutive quarters of revenue growth.
Enzo Biochem's strategic focus on high-growth market segments like drug development and cell and gene therapy is well-timed, given the increasing investment and innovation in these areas. By positioning itself in these niches, Enzo is capitalizing on industry trends that are driving demand for specialized life science products. The company's emphasis on quality customer service, supported by a stable global infrastructure, is a competitive advantage that can lead to customer retention and potentially attract new business.
The company's operational progress, as highlighted by the CEO, suggests a successful execution of their business strategy. The reported financials provide evidence of Enzo's ability to not only increase revenue but also to translate that into actual profit, a key determinant of a company's value to investors. As Enzo continues to execute its strategy, stakeholders should monitor the company's ability to maintain these margins and growth rates in a dynamic and competitive market.
The biotechnology sector is known for its high research and development costs, which often result in long periods before profitability is achieved. Enzo Biochem's improvement in gross margins by 1,000 basis points is therefore an exceptional development, indicating that the company is progressing well beyond industry norms in terms of cost management and operational efficiency.
The focus on drug development and cell and gene therapy is strategic, as these are areas with significant barriers to entry due to the scientific complexity and regulatory requirements involved. Enzo's success in these segments suggests a high level of technical expertise and the ability to navigate the regulatory landscape effectively. The improved profitability in the Life Science division, despite the traditionally high costs associated with these market segments, is a testament to the company's strategic planning and execution.
However, the reported decrease in cash reserves may raise questions about the sustainability of the current growth rate. It is crucial for Enzo to balance its investment in growth with the management of its cash flow to ensure long-term viability. The reduction in cash reserves could be a strategic move to optimize the balance sheet post the clinical lab asset sale, but it is essential to observe how this will affect the company's ability to fund future growth initiatives.
FARMINGDALE, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the second quarter ended January 31, 2024.
Second Quarter Highlights
- The Company's Life Science division's second-quarter revenue of
$8.5 million improved year-over-year by14% . During the 2024 period, we experienced a25% revenue increase in the United States, driven by increased product demand in the drug development and cell and gene therapy market segments. Revenue for the six months ended January 31, 2024 of$16.4 million improved12% compared to the same period in the prior year. - The Life Science division's second-quarter gross margin was
49% , which improved by 1,000 basis points year-over-year from39% , and was also a sequential 500 basis point improvement from44% . The six-month YTD margin was47% which was also a 1,000 basis point improvement compared to the prior year. This favorable result was driven by the reported revenue increase, mix of products sold, and ongoing cost containment initiatives, including, but not limited to, a workforce reduction for continuing operations. - The Life Science division reported second-quarter net income of
$1.1 million , compared to net income of$0.2 million in the prior year period. The net loss in the Corporate & Other segment decreased year-over-year by$1.2 million . - Enzo ended the second quarter with aggregate cash and cash equivalents of
$60.2 million , a reduction of$23.1 million from July 31, 2023, primarily due to the significant paydown of accounts payable and accrued liabilities post the clinical lab asset sale. The Company’s current ratio was 3.2 as of January 31, 2024. - Net loss from continuing operations for Q2 FY24 was
$0.9 million or ($0.02) per common share, compared to a net loss in the prior year’s second quarter of$2.9 million or ($0.06) per common share. - Net loss, representing the results of continuing and discontinued operations for Q2 FY24, was
$3.1 million , or ($0.06) per common share, compared to a net loss in the prior year’s second quarter of$11.3 million , or ($0.23) per common share. The weighted average basic common shares outstanding as of January 31, 2024, was 50.5 million.
“Enzo’s strategy is to deliver sustainable, profitable revenue growth through market focus, technical strength, and operational conservatism. We are pleased to report a third consecutive quarter with double-digit revenue growth in the life science division, and I am proud of the team's hard work resulting in higher gross margin and improved profitability in the second quarter within our Life Science division,” said Kara Cannon, Enzo’s Chief Executive Officer. These achievements were driven by aligning our products in high-growth market segments made up of our drug development customers, while relying on our existing, stable global infrastructure to provide comprehensive, quality customer service. I am very encouraged by our financial and operational progress, and I am optimistic about our ability to maintain this positive momentum to deliver on longer-term goals.”
Enzo Biochem, a pioneer in molecular diagnostics, contributes to advancing healthcare with its comprehensive portfolio of technical platforms and reagent sets supporting a diverse range of biomedical research and translational science needs. A leader in innovation and product development for over 45 years, scientists have trusted Enzo Biochem to manufacture and supply a comprehensive portfolio of thousands of high-quality products, including antibodies, genomic probes, assays, biochemicals, and proteins. The Company’s proprietary products and technologies play central roles in all translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. Enzo Biochem, Inc.’s Life Science division supports the work of research centers and industry partners, shaping the future of healthcare worldwide. Enzo Biochem, Inc. has a broad and deep intellectual property portfolio, with patent coverage across many vital enabling technologies. For more information, please visit Enzo.com or follow Enzo Biochem on X and LinkedIn.
Forward-Looking Statements
Except for historical information, the matters discussed in this release may be considered "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements include declarations regarding the intent, belief or current expectations of the Company and its management, including those related to cash flow, gross margins, revenues, and expenses which are dependent on a number of factors outside of the control of the Company including, inter alia, the markets for the Company’s products, cost of goods sold, other expenses, government regulations, litigation, and general business conditions. See Risk Factors in the Company’s Form 10-K for the fiscal year ended July 31, 2023. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve a number of risks and uncertainties that could materially affect actual results. The Company disclaims any obligations to update any forward-looking statement as a result of developments occurring after the date of this release.
| Enzo Biochem Contacts |
| For Enzo Biochem: |
| Patricia Eckert, Chief Financial Officer Enzo Biochem 631-755-5500 peckert@enzo.com |
Use of Non-GAAP Financial Measures by Enzo
The non-GAAP financial measures contained in this press release (including, without limitation, Adjusted net income (loss), EBITDA, and Adjusted EBITDA), are not GAAP measures of the Company’s financial performance or liquidity and should not be considered as alternatives to net income (loss) as a measure of financial performance or cash flows from operations as measures of liquidity, or any other performance measure derived in accordance with GAAP. A reconciliation of such non-GAAP measures is included in the presentation of the Company’s financial results for the second quarter ended January 31, 2024 contained herein and is also available in the investor relations section of the Company’s website (https://www.enzo.com).
The Company believes the presentation of these non-GAAP measures provides useful additional information to investors because they provide information consistent with that on which management evaluates the financial performance of the Company. The Company manages its business based on its operating cash flows. It refers to EBITDA as its primary indicator of performance, and refers to Adjusted EBITDA to further exclude items of a non-recurring nature. It is reasonable to expect that one or more excluded items will occur in future periods, though the amounts recognized can vary significantly from period to period. You are encouraged to evaluate each adjustment to a non-GAAP financial measure and the reasons management considers it appropriate for supplemental analysis. Our presentation of these measures should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items.
We refer you to the tables attached to this press release, which includes reconciliation tables of GAAP net income (loss) to Adjusted net income (loss) and GAAP net income (loss) to EBITDA and Adjusted EBITDA.
| ENZO BIOCHEM, INC. | |||||||||||||||
| (in thousands, except per share data) | |||||||||||||||
| Three months ended | Six months ended | ||||||||||||||
| Selected operations data: | January 31, | January 31, | |||||||||||||
| (unaudited) | (unaudited) | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Revenues | $ | 8,553 | $ | 7,514 | $ | 16,359 | $ | 14,617 | |||||||
| Gross profit | 4,224 | 2,898 | 7,679 | 5,412 | |||||||||||
| Gross profit % | 49 | % | 39 | % | 47 | % | 37 | % | |||||||
| Operating loss | (2,185 | ) | (4,545 | ) | (7,655 | ) | (9,173 | ) | |||||||
| Net loss from continuing operations | (863 | ) | (2,892 | ) | (6,538 | ) | (8,245 | ) | |||||||
| Net loss from discontinued operations | (2,198 | ) | (8,428 | ) | (3,139 | ) | (13,710 | ) | |||||||
| Net loss | $ | (3,061 | ) | $ | (11,320 | ) | $ | (9,677 | ) | $ | (21,955 | ) | |||
| Net loss per common share- basic and diluted- Continuing Operations | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Net loss per common share- basic and diluted- Discontinued Operations | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Total net loss per basic and diluted common share | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Weighted average common shares outstanding - basic and diluted | 50,490 | 48,729 | 50,337 | 48,725 | |||||||||||
| Selected balance sheet data: | 1/31/2024 (unaudited) | 7/31/2023 (unaudited) | |||||||||||||
| Cash and cash equivalents (includes restricted cash of | $ | 60,241 | $ | 83,373 | |||||||||||
| Working capital | 55,637 | 58,467 | |||||||||||||
| Stockholders' equity | 70,775 | 78,462 | |||||||||||||
| Total assets | 99,077 | 121,880 | |||||||||||||
| The following table presents a reconciliation of reported net loss and basic and diluted net loss per share to adjusted net income (loss) and basic and diluted net loss per share adjusted, for the three and six months ended January 31, 2024 and 2023: | |||||||||||||||
| ENZO BIOCHEM, INC. | |||||||||||||||
| Adjusted Net income (loss) Reconciliation Table | |||||||||||||||
| (Unaudited, in thousands, except per share data) | |||||||||||||||
| Three months ended | Six months ended | ||||||||||||||
| January 31, | January 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| Reported GAAP net loss | $ | (3,061 | ) | $ | (11,320 | ) | $ | (9,677 | ) | $ | (21,955 | ) | |||
| Adjusted for: | |||||||||||||||
| Discrete legal matters | 613 | 174 | 1,476 | 196 | |||||||||||
| Fair value adjustment | 383 | - | 711 | - | |||||||||||
| Discrete separation expenses | 69 | 982 | 1,742 | 1,808 | |||||||||||
| Strategic initiative expenses | - | 759 | - | 1,648 | |||||||||||
| Discontinued operations loss | 2,198 | 8,428 | 3,139 | 13,710 | |||||||||||
| Adjusted net income (loss) | $ | 202 | $ | (977 | ) | $ | (2,609 | ) | $ | (4,593 | ) | ||||
| Weighted Shares Outstanding: | |||||||||||||||
| Basic and diluted | 50,490 | 48,729 | 50,337 | 48,725 | |||||||||||
| Basic and diluted earnings per share: | |||||||||||||||
| Basic and diluted net income (loss) per share GAAP | ( | ) | ( | ) | ( | ) | ( | ) | |||||||
| Basic and diluted net income (loss) per share adjusted | ( | ) | ( | ) | ( | ) | |||||||||
| The following table presents a reconciliation of reported GAAP net loss for the three and six months ended January 31, 2024 and 2023, respectively to EBITDA and Adjusted EBITDA: | |||||||||||||||
| ENZO BIOCHEM, INC. | |||||||||||||||
| EBITDA & Adjusted EBITDA Reconciliation Table | |||||||||||||||
| (Unaudited, in thousands) | |||||||||||||||
| Three months ended | Six months ended | ||||||||||||||
| January 31, | January 31, | ||||||||||||||
| 2024 | 2023 | 2024 | 2023 | ||||||||||||
| GAAP net loss | $ | (3,061 | ) | $ | (11,320 | ) | $ | (9,677 | ) | $ | (21,955 | ) | |||
| Plus (minus): | |||||||||||||||
| Depreciation and amortization | 267 | 262 | 537 | 510 | |||||||||||
| Interest income, net | (893 | ) | (63 | ) | (1,870 | ) | (135 | ) | |||||||
| EBITDA | (3,687 | ) | (11,121 | ) | (11,010 | ) | (21,580 | ) | |||||||
| Adjusted for: | |||||||||||||||
| Discrete legal matters | 613 | 174 | 1,476 | 196 | |||||||||||
| Fair value adjustment | 383 | - | 711 | - | |||||||||||
| Discrete separation expenses | 69 | 982 | 1,742 | 1,808 | |||||||||||
| Strategic initiative expenses | - | 759 | - | 1,648 | |||||||||||
| Discontinued operations loss | 2,198 | 8,428 | 3,139 | 13,710 | |||||||||||
| Foreign exchange (gain) loss | (693 | ) | (1,472 | ) | 318 | (675 | ) | ||||||||
| Adjusted EBITDA | $ | (1,117 | ) | $ | (2,250 | ) | $ | (3,624 | ) | $ | (4,893 | ) | |||
FAQ
What was the revenue growth percentage for the Life Science division in the second quarter?
What was the gross margin percentage for the Life Science division in the second quarter?
What was the net income for the second quarter?
How much cash and cash equivalents did Enzo have at the end of the second quarter?
What is Enzo's strategy for revenue growth?
